Skip to main content
BAX
NYSE Industrial Applications And Services

Baxter Seeks Shareholder Approval for 20M New Incentive Shares and Executive Compensation Amidst Turnaround

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$18
Mkt Cap
$9.266B
52W Low
$17
52W High
$35.77
52W Position info
5.9% above low
Off High info
50% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

BAX is trading near its 52-week low of $17 (5.9% above the low).

Summary

Baxter International is seeking shareholder approval for a significant increase in its equity incentive plan shares, potentially diluting existing shareholders by nearly 4%, and has disclosed substantial executive compensation amidst a challenging financial year.


Key Events · Corporate Governance and Compliance · BAX

  • Proposed Increase in Equity Incentive Plan Shares

    The company is requesting shareholder approval to increase the aggregate number of shares authorized for its 2021 Incentive Plan by 20,000,000, bringing the total available to 44,050,285. This represents a potential dilution of approximately 3.88% based on current outstanding shares.

  • Significant Executive Compensation Disclosed

    The filing details 2025 executive compensation, including CEO Andrew Hider's total compensation of $29.8 million and former CEO José Almeida's $6.89 million lump-sum termination payment. This comes amidst a year of significant net losses and impairments for the company.

  • Board Composition Changes and Flexibility

    Several changes to the Board of Directors are noted, including the appointment of Michael McDonnell, the resignations of Cathy Smith and Stephen Rusckowski, and the upcoming retirement of Dr. Stephen Oesterle. The company also proposes amending its Certificate of Incorporation to reduce the minimum board size from nine to five directors, providing greater flexibility for future board refreshment.

  • Executive Pay Aligned with Challenging Performance

    Annual incentive plan payouts for NEOs ranged from 52% to 61% of target, and Performance Share Unit (PSU) payouts for the 2023-2025 cycle were 57% of target, reflecting the company's challenging financial performance in 2025.


Analysis · BAX · Industrial Applications And Services

This preliminary proxy statement outlines key proposals for Baxter's upcoming annual meeting, which are particularly significant given the company's stated 'turnaround' efforts and recent financial challenges, including a 'significant net loss and substantial impairments' in 2025. The request for 20 million additional shares for the incentive plan represents a notable potential dilution of approximately 3.88% to existing shareholders. While framed as essential for attracting and retaining talent during a critical transformation, this dilution is a material consideration. Furthermore, the disclosure of substantial executive compensation, including CEO Andrew Hider's $29.8 million total compensation and a $6.89 million termination payment to former CEO José Almeida, will likely draw scrutiny given the company's poor financial performance in the past year. The board changes and governance updates, while positive in intent, are overshadowed by these financial and dilutive aspects.

At the time of this filing, BAX was trading at $18.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9.3B. The 52-week trading range was $17.00 to $35.77. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BAX - Latest Insights

BAX
May 08, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $17.99
Real-time Price: $24.50 info
Change: +$6.51 (+36%) info
Market Cap: $12.586B info
BAX
May 08, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.01
Real-time Price: $24.50 info
Change: +$6.49 (+36%) info
Market Cap: $12.586B info
BAX
Apr 30, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $17.44
Real-time Price: $24.50 info
Change: +$7.06 (+40%) info
Market Cap: $12.586B info
BAX
Apr 30, 2026, 7:28 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $17.75
Real-time Price: $24.50 info
Change: +$6.75 (+38%) info
Market Cap: $12.586B info
BAX
Apr 30, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $17.33
Real-time Price: $24.50 info
Change: +$7.17 (+41%) info
Market Cap: $12.586B info